Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer

  • Lee, Kyung Ann (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Lee, Jong Sik (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Min, Jae Ki (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Kim, Hee Joung (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Kim, Wan Seop (Department of Pathology, Konkuk University School of Medicine) ;
  • Lee, Kye Young (Department of Internal Medicine, Konkuk University School of Medicine)
  • Received : 2014.07.03
  • Accepted : 2014.09.21
  • Published : 2014.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Anaplastic lymphoma kinase (ALK) rearrangement, is a kind of driver mutation, accounts for 3%-5% of non-small cell lung cancer (NSCLC). NSCLC patients harboring ALK fusion genes have distinct clinical features and good response to ALK inhibitors. Metastasis from lung cancer to the ovary has rarely been known. We report a case of a 54-year-old woman with bilateral ovarian metastases from ALK rearranged NSCLC. She underwent bilateral salpingo-oophorectomy for ovary masses, which were progressed after cytotoxic chemotherapy although primary lung mass was decreased. Histopathological examination of the ovary tumor showed characteristic adenocarcinoma patterns of the lung and ALK rearrangement.

Keywords

References

  1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. https://doi.org/10.1038/nature05945
  2. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46:1773-80. https://doi.org/10.1016/j.ejca.2010.04.002
  3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010;363:1693-703. https://doi.org/10.1056/NEJMoa1006448
  4. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94. https://doi.org/10.1056/NEJMoa1214886
  5. Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013;73:2031-51. https://doi.org/10.1007/s40265-013-0142-z
  6. Hayashi H, Okamoto I, Tanizaki J, Tanaka K, Okuda T, Kato A, et al. Cystic brain metastasis in non-small-cell lung cancer With ALK rearrangement. J Clin Oncol 2014;32:e122-4.. https://doi.org/10.1200/JCO.2012.48.2141
  7. Alvarado-Cabrero I, Rodriguez-Gomez A, Castelan-Pedraza J, Valencia-Cedillo R. Metastatic ovarian tumors: a clinicopathologic study of 150 cases. Anal Quant Cytopathol Histpathol 2013;35:241-8.
  8. Jung YE, Lee JW, Kim BG, Bae DS. Ovarian metastasis from pulmonary adenocarcinoma. Obstet Gynecol Sci 2013;56: 341-4. https://doi.org/10.5468/ogs.2013.56.5.341
  9. Fujiwara K, Ohishi Y, Koike H, Sawada S, Moriya T, Kohno I. Clinical implications of metastases to the ovary. Gynecol Oncol 1995;59:124-8. https://doi.org/10.1006/gyno.1995.1278
  10. Irving JA, Young RH. Lung carcinoma metastatic to the ovary: a clinicopathologic study of 32 cases emphasizing their morphologic spectrum and problems in differential diagnosis. Am J Surg Pathol 2005;29:997-1006.
  11. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012;118:4502-11. https://doi.org/10.1002/cncr.27409
  12. Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, et al. Worse disease-free survival in neversmokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012;7:90-7. https://doi.org/10.1097/JTO.0b013e31823c5c32

Cited by

  1. Uterine Cervix Metastasis in Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Rearrangement vol.21, pp.2, 2014, https://doi.org/10.15746/sms.15.033
  2. Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis : A Case Report vol.95, pp.30, 2014, https://doi.org/10.1097/md.0000000000004221
  3. Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review vol.18, pp.5, 2014, https://doi.org/10.1080/15384047.2017.1310344
  4. Adenocarcinoma of the Lung Metastatic to the Ovary With a Signet Ring Cell Component vol.25, pp.4, 2014, https://doi.org/10.1177/1066896917691613
  5. Female genital tract metastasis of lung adenocarcinoma with EGFR mutations: Report of two cases vol.7, pp.12, 2014, https://doi.org/10.12998/wjcc.v7.i12.1515
  6. ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma vol.14, pp.1, 2019, https://doi.org/10.1186/s13000-019-0864-7